Duvic,
M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., ... &
Frankel, S. R. (2007). Phase 2 trial of oral vorinostat (suberoylanilide
hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma
(CTCL). Blood, 109(1), 31-39.
Marks, P. A., & Breslow, R. (2007). Dimethyl sulfoxide to
vorinostat: development of this histone deacetylase inhibitor as an
anticancer drug. Nature biotechnology, 25(1), 84-90.
Shankar, S., Davis, R., Singh, K. P., Kurzrock, R., Ross, D. D.,
& Srivastava, R. K. (2009). Suberoylanilide hydroxamic acid
(Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells
orthotopically implanted in BALB/c nude mice. Molecular cancer therapeutics, 8(6), 1596-1605.